Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data

被引:10
|
作者
Hoa Van Le [1 ]
Chi Thi Le Truong [2 ]
Kamauu, Aaron W. C. [1 ,3 ]
Holmen, John [4 ]
Fillmore, Christopher [4 ]
Kobayashi, Monica G. [1 ]
Martin, Canter [1 ]
Sabido, Meritxell [5 ]
Wong, Schiffon L. [6 ]
机构
[1] PAREXEL Int, Durham, NC USA
[2] MedCodeWorld, Mississauga, ON, Canada
[3] Anolinx LLC, Salt Lake City, UT USA
[4] Intermt Healthcare, Murray, UT USA
[5] Merck KGaA, Darmstadt, Germany
[6] EMD Serono Inc, 45A Middlesex Turnpike, Billerica, MA 01821 USA
关键词
algorithm; claims; electronic health records; multiple sclerosis; relapsing-remitting multiple sclerosis; AUTOMATED EXTRACTION; DISABILITY;
D O I
10.1016/j.jval.2018.06.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Relapsing-remitting multiple sclerosis (RRMS) has a major impact on affected patients; therefore, improved understanding of RRMS is important, particularly in the context of real-world evidence. Objectives: To develop and validate algorithms for identifying patients with RRMS in both unstructured clinical notes found in electronic health records (EHRs) and structured/coded health care claims data. Methods: US Integrated Delivery Network data (2010-2014) were queried for study inclusion criteria (possible multiple sclerosis [MS] base cohort): one or more MS diagnosis code, patients aged 18 years or older, 1 year or more baseline history, and no other demyelinating diseases. Sets of algorithms were developed to search narrative text of unstructured clinical notes (EHR clinical notes-based algorithms) and structured/coded data (claims-based algorithms) to identify adult patients with RRMS, excluding patients with evidence of progressive MS. Medical records were reviewed manually for algorithm validation. Positive predictive value was calculated for both EHR clinical notes-based and claims-based algorithms. Results: From a sample of 5308 patients with possible MS, 837 patients with RRMS were identified using only the EHR clinical notes-based algorithms and 2271 patients were identified using only the claims-based algorithms; 779 patients were identified using both algorithms. The positive predictive value was 99.1% (95% confidence interval [CI], 94.2%-100%) for the EHR clinical notes-based algorithms and 94.6% (95% CI, 89.1%-97.8%) to 94.9% (95% CI, 89.8%-97.9%) for the claims-based algorithms. Conclusions: The algorithms evaluated in this study identified a real-world cohort of patients with RRMS without evidence of progressive MS that can be studied in clinical research with confidence. Copyright (c) 2019, ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [31] Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data
    Jacqueline A. Nicholas
    Batul Electricwala
    Lulu K. Lee
    Kristen M. Johnson
    BMC Neurology, 19
  • [32] Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data
    Nicholas, Jacqueline A.
    Electricwala, Batul
    Lee, Lulu K.
    Johnson, Kristen M.
    BMC NEUROLOGY, 2019, 19 (01)
  • [33] Significance of the Diagnosis of Executive Functions in Patients with Relapsing-Remitting Multiple Sclerosis
    Borkowska, Aneta R.
    Daniluk, Beata
    Adamczyk, Katarzyna
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (19)
  • [34] Serum uric acid level in patients with relapsing-remitting multiple sclerosis
    Ashtari, Fereshteh
    Bahar, Mohammadali
    Aghaei, Maryam
    Zahed, Arash
    JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (05) : 676 - 678
  • [35] Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients
    Cavallari, Michele
    Palotai, Miklos
    Glanz, Bonnie I.
    Egorova, Svetlana
    Prieto, Juan Carlos
    Healy, Brian C.
    Chitnis, Tanuja
    Guttmann, Charles R. G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (14) : 1841 - 1849
  • [36] New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
    Fox, Edward J.
    Rhoades, Robert W.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 : S11 - S19
  • [37] Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Conte, A.
    Lenzi, D.
    Frasca, V.
    Gilio, F.
    Giacomelli, E.
    Gabriele, M.
    Bettolo, C. Marini
    Iacovelli, E.
    Pantano, P.
    Pozzilli, C.
    Inghilleri, M.
    JOURNAL OF NEUROLOGY, 2009, 256 (06) : 933 - 938
  • [38] Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
    Taskapilioglu, Ozlem
    Turan, Asli Bahar
    Albas, Murat
    Turan, Omer Faruk
    TURKISH JOURNAL OF NEUROLOGY, 2012, 18 (01) : 17 - 20
  • [39] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [40] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13